| Identification | Back Directory | [Name]
1H-Isoindole-1,3(2H)-dione, 4-[[6-[4-[2-(4-amino-5-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1H-benzimidazol-6-yl]-1-piperazinyl]-6-oxohexyl]amino]-2-(2,6-dioxo-3-piperidinyl)- | [CAS]
2732969-67-2 | [Synonyms]
Pomalidomide-C5-Dovitinib
1H-Isoindole-1,3(2H)-dione, 4-[[6-[4-[2-(4-amino-5-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1H-benzimidazol-6-yl]-1-piperazinyl]-6-oxohexyl]amino]-2-(2,6-dioxo-3-piperidinyl)-
4-[(6-{4-[2-(4-amino-5-fluoro-2-oxo-1,2-dihydroquinolin-3-yl)-1H-1,3-benzodiazol-6-yl]piperazin-1-yl}-6-oxohexyl)amino]-2-(2,6-dioxopiperidin-3-yl)-2,3-dihydro-1H-isoindole-1,3-dione | [Molecular Formula]
C39H38FN9O6 | [MOL File]
2732969-67-2.mol | [Molecular Weight]
747.77 |
| Hazard Information | Back Directory | [Uses]
Pomalidomide-C5-Dovitinib (compound 2) is a PROTAC containing Pomalidomide, Dovitinib and connected with CRBN. Pomalidomide-C5-Dovitinib shows enhanced antiproliferative effects against FLT3-ITD+ AML cells. Pomalidomide-C5-Dovitinib induces the degradation of the FLT3-ITD and KIT proteins in a ubiquitin-proteasome-dependent manner and completely blocks their downstream signaling pathway. Pomalidomide-C5-Dovitinib has the potential for the research of FLT3-ITD+ acute myeloid leukemia[1]. | [References]
[1] Cao S, et al. Proteolysis-Targeting Chimera (PROTAC) Modification of Dovitinib Enhances the Antiproliferative Effect against FLT3-ITD-Positive Acute Myeloid Leukemia Cells. J Med Chem. 2021;64(22):16497-16511. DOI:10.1021/acs.jmedchem.1c00996 |
|
|